Telik Announces Presentation and Webcast at 14th Annual BIO CEO & Investor Conference
PALO ALTO, Calif., Feb. 8, 2012 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today announced that CEO Michael M. Wick, M.D., Ph.D. will provide a corporate overview at the 14th Annual BIO CEO & Investor Conference in New York City on Tuesday, February 14 at 1:00 p.m. Eastern time (10:00 a.m. Pacific time), in the Waldorf-Astoria Hotel's Conrad Suite . A live and archived webcast of the presentation will be available on the Telik website, www.telik.com. The archived broadcast of the presentation can be accessed for 30 days following the presentation.
About Telik
Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The company's most advanced drug candidate is Telintra®, a modified glutathione analog intended for the treatment of hematologic malignancies including myelodysplastic syndrome; followed by Telcyta®, a cancer activated prodrug for the treatment of a variety of cancers. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.
Telik, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.
SOURCE Telik, Inc.
RELATED LINKS
http://www.telik.com
More by this Source
Telik Announces First Quarter 2013 Financial Results
May 10, 2013, 16:30 ET
Telik Announces Fourth Quarter And 2012 Year End Financial Results And 2013 Financial Guidance
Mar 15, 2013, 16:30 ET
Telik Announces Preliminary Agreement On Design Of Phase 3 Registration Trial Of Telintra® In Low To Intermediate-1 Risk Myelodysplastic Syndrome
Jan 22, 2013, 17:30 ET
Featured Video
Journalists and Bloggers
Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.
View and download archived video content distributed by MultiVu on The Digital Center.
Custom Packages
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.